Phase I study of liposomal annamycin
β Scribed by Daniel J. Booser; Roman Perez-Soler; Paul Cossum; Laura Esparza-Guerra; Qing-Ping Wu; Yiyu Zou; Waldemar Priebe; Gabriel N. Hortobagyi
- Publisher
- Springer
- Year
- 2000
- Tongue
- English
- Weight
- 98 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEGβLD) and gemcitabine have singleβagent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie
## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEGβLD) and docetaxel have singleβagent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad